SMT201400126B - Uso di amisulpride per il trattamento di nausea e vomito post-operatori - Google Patents

Uso di amisulpride per il trattamento di nausea e vomito post-operatori

Info

Publication number
SMT201400126B
SMT201400126B SM201400126T SM201400126T SMT201400126B SM T201400126 B SMT201400126 B SM T201400126B SM 201400126 T SM201400126 T SM 201400126T SM 201400126 T SM201400126 T SM 201400126T SM T201400126 B SMT201400126 B SM T201400126B
Authority
SM
San Marino
Prior art keywords
amisulpride
vomiting
post
treatment
operative nausea
Prior art date
Application number
SM201400126T
Other languages
English (en)
Italian (it)
Inventor
Nicola Cooper
Julian Clive Gilbert
Robert William Gristwood
Gabriel Fox
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201400126(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of SMT201400126B publication Critical patent/SMT201400126B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SM201400126T 2010-03-11 2014-09-10 Uso di amisulpride per il trattamento di nausea e vomito post-operatori SMT201400126B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use
PCT/GB2011/050472 WO2011110854A2 (en) 2010-03-11 2011-03-10 The use of amisulpride as an anti-emetic

Publications (1)

Publication Number Publication Date
SMT201400126B true SMT201400126B (it) 2015-05-05

Family

ID=42136792

Family Applications (2)

Application Number Title Priority Date Filing Date
SM201400127T SMT201400127B (it) 2010-03-11 2014-09-10 Uso di amisulpride per il trattamento di nausea e vomito indotti da chemioterapia
SM201400126T SMT201400126B (it) 2010-03-11 2014-09-10 Uso di amisulpride per il trattamento di nausea e vomito post-operatori

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM201400127T SMT201400127B (it) 2010-03-11 2014-09-10 Uso di amisulpride per il trattamento di nausea e vomito indotti da chemioterapia

Country Status (27)

Country Link
US (11) US8686019B2 (xx)
EP (3) EP2796171B1 (xx)
JP (2) JP5886213B2 (xx)
KR (1) KR101738201B1 (xx)
CN (1) CN102892407B (xx)
AU (1) AU2011225898B2 (xx)
BR (1) BR112012022746B1 (xx)
CA (1) CA2792392C (xx)
CY (3) CY1115485T1 (xx)
DK (3) DK2796171T3 (xx)
EA (1) EA030335B1 (xx)
ES (3) ES2665418T3 (xx)
GB (1) GB201004020D0 (xx)
HK (1) HK1179152A1 (xx)
HR (3) HRP20140744T1 (xx)
HU (1) HUE037088T2 (xx)
IL (1) IL221746A (xx)
LT (1) LT2796171T (xx)
MX (3) MX2012010411A (xx)
NO (1) NO2796171T3 (xx)
NZ (1) NZ602279A (xx)
PL (3) PL2796171T3 (xx)
PT (3) PT2567690E (xx)
RS (3) RS57032B1 (xx)
SI (3) SI2796171T1 (xx)
SM (2) SMT201400127B (xx)
WO (1) WO2011110854A2 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
EP3344962A4 (en) 2015-09-02 2019-03-13 California Institute of Technology METHOD AND APPARATUS FOR SPECTROSCOPIC DETECTION OF LOW HYDROGEN SULFIDE CONCENTRATIONS GASEOUS
GB201618425D0 (en) 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
SG11202005016SA (en) 2017-12-05 2020-06-29 Sunovion Pharmaceuticals Inc Nonracemic mixtures and uses thereof
JP2021505595A (ja) 2017-12-05 2021-02-18 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 結晶形およびその製造方法
WO2020247603A1 (en) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN114401717A (zh) * 2019-06-04 2022-04-26 赛诺维信制药公司 修饰释放配制品及其用途
CN115867271A (zh) * 2020-07-06 2023-03-28 阿卡西亚制药有限公司 术后恶心和呕吐的疗法
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024138048A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US20070190145A1 (en) * 2006-01-27 2007-08-16 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
US8124126B2 (en) * 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
NZ602279A (en) 2014-08-29
MX2019015396A (es) 2020-02-07
MX370629B (es) 2019-12-18
CY1115487T1 (el) 2017-01-04
PT2796171T (pt) 2018-04-24
CY1115485T1 (el) 2017-01-04
AU2011225898B2 (en) 2014-07-03
ES2496099T3 (es) 2014-09-18
US9084765B2 (en) 2015-07-21
CN102892407B (zh) 2016-03-23
CY1120170T1 (el) 2018-12-12
RS53466B (en) 2014-12-31
US20210228543A1 (en) 2021-07-29
EA201290833A1 (ru) 2013-09-30
MX2012010411A (es) 2012-11-30
HRP20180436T1 (hr) 2018-05-04
US20130022688A1 (en) 2013-01-24
LT2796171T (lt) 2018-05-10
DK2796171T3 (en) 2018-05-07
RS57032B1 (sr) 2018-05-31
KR101738201B1 (ko) 2017-05-19
US20130022689A1 (en) 2013-01-24
US9545426B2 (en) 2017-01-17
PT2544657E (pt) 2014-09-03
US20220296570A1 (en) 2022-09-22
RS53467B (en) 2014-12-31
US20150335616A1 (en) 2015-11-26
ES2496092T3 (es) 2014-09-18
US9889118B2 (en) 2018-02-13
PL2544657T3 (pl) 2014-10-31
US20200093792A1 (en) 2020-03-26
CA2792392A1 (en) 2011-09-15
EP2796171B1 (en) 2018-01-31
HRP20140745T1 (hr) 2014-09-26
EP2544657A2 (en) 2013-01-16
HK1179152A1 (zh) 2013-09-27
EP2796171A1 (en) 2014-10-29
PL2567690T3 (pl) 2014-11-28
ES2665418T3 (es) 2018-04-25
SI2796171T1 (en) 2018-05-31
DK2544657T3 (da) 2014-08-11
CN102892407A (zh) 2013-01-23
JP2013522181A (ja) 2013-06-13
US20170087128A1 (en) 2017-03-30
PT2567690E (pt) 2014-09-03
GB201004020D0 (en) 2010-04-21
AU2011225898A1 (en) 2012-10-04
BR112012022746B1 (pt) 2021-09-28
US9119836B2 (en) 2015-09-01
KR20130045241A (ko) 2013-05-03
DK2567690T3 (da) 2014-08-11
SI2567690T1 (sl) 2014-12-31
CA2792392C (en) 2018-06-19
EP2567690B1 (en) 2014-07-16
EP2544657B1 (en) 2014-07-16
US20140147517A1 (en) 2014-05-29
US10525033B2 (en) 2020-01-07
WO2011110854A2 (en) 2011-09-15
EA030335B1 (ru) 2018-07-31
NO2796171T3 (xx) 2018-06-30
SI2544657T1 (sl) 2014-12-31
EP2567690A1 (en) 2013-03-13
US20180353473A1 (en) 2018-12-13
US20230144973A1 (en) 2023-05-11
BR112012022746A2 (pt) 2016-07-05
US20180042896A1 (en) 2018-02-15
JP5886213B2 (ja) 2016-03-16
US10085970B2 (en) 2018-10-02
HRP20140744T1 (hr) 2014-09-26
IL221746A (en) 2017-03-30
HUE037088T2 (hu) 2018-08-28
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (en) 2011-11-10
SMT201400127B (it) 2015-05-05
JP2016028090A (ja) 2016-02-25
US8686019B2 (en) 2014-04-01
JP6279526B2 (ja) 2018-02-14

Similar Documents

Publication Publication Date Title
SMT201400126B (it) Uso di amisulpride per il trattamento di nausea e vomito post-operatori
SMT201400008B (it) Uso di betanecolo per il trattamento di xerostomia
EP2524243A4 (en) Portable dosimeter
EP2629975A4 (en) Devices, systems, and methods for the fabrication of tissue
FR2957244B1 (fr) Implant d'arthrodese
EP2616843A4 (en) Portable dosimeter
BR112013004025A2 (pt) amarra para uso hortícola
EP2625720A4 (en) Support structure and systems including the same
SMT201700064B (it) Antagonisti di d2, metodi di sintesi e metodi di uso
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
CO6781486A2 (es) Compuestos y su uso
ZA201208895B (en) Bicyclic compound derivatives and their use as acc inhibitors
EP2656900A4 (en) Honeycomb structure
ZA201300036B (en) Banzamide derivatives and their use as hsp90 inhibitors
FI20106240A0 (fi) Lähetinvastaanotinyksikkö
EP2637418A4 (en) Oscillator and portable device
EP2656901A4 (en) Honeycomb structure
IT1401350B1 (it) Veicolo - ambulanza per il trasporto di pazienti, feriti e simili
FI20100404A0 (fi) Yhteysalus
BRPI1009090A2 (pt) composto, pró-droga, medicamento, métodos, e, uso do composto
CL2012003460A1 (es) Compuestos derivados de 3-aminolactama aril sustituidas; composicion farmaceutica; y uso en el tratamiento de la inflamacion.
EP2558655A4 (en) Generator and bidet comprising the same
FR2967701B1 (fr) Structure d'absorption acoustique faiblement combustible
IT1402253B1 (it) Impianto e procedimento per il trattamento di reflui inquinanti